No CrossRef data available.
Article contents
Where are we Going with Drugs to Treat MS? Will Cost Continue to Increase?
Published online by Cambridge University Press: 02 December 2014
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Editorial
- Information
- Copyright
- Copyright © The Canadian Journal of Neurological 2010
References
1.
Rotstein, DL, Mamdani, M, O’Connor, PW.
Increasing use of disease modifying drugs for MS in Canada. Can J Neurol Sci. 2010; 37:383–8.Google Scholar
2.
Tremlett, HL, Oger, J.
Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler.
2008 Jan;14(1):94–105.Google Scholar
3.
Cohen, JA, Barkhof, F, Comi, G, Hartung, HP, Khatri, BO, Montalban, X, et al.
Oral fingolimod or intramuscular interferon for relapsing multiple Sclerosis. N Engl J Med.
2010;362(5):402–15.CrossRefGoogle ScholarPubMed
4.
Giovannoni, G, Comi, G, Cook, S, Rammohan, K, Rieckmann, P, Sorensen, PS, et al.
A placebo-controlled trial of Oral Cladribine for relapsing MS. N Engl J Med.
2010;362(5):416–26.Google Scholar
5.
Government of Canada, Social Union, News release. A framework to improve the social union for Canadians an agreement between the Government of Canada and the Governments of the Provinces February 4, 1999 [cited 2010 Jan 23/] Available from: http://www.socialunion.gc.ca/news/024992.html
Google Scholar
6.
Thanassoulis, G, Karp, I, Humphries, K, Tu, JV, Eisenberg, MJ, Pilote, L.
Impact of restrictive prescription plans on heart failure medication use. Circ Cardiovasc Qual Outcomes.
2009 Sep;2(5):484–90.Google Scholar
7.
Neutel, CI, Patten, SB.
Sleep medication use in Canadian Seniors. Can J Pharmaco. 2009 Fall;16(3):e443–52.Google Scholar
You have
Access